About: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 October 1996

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 1996 (uk) article scientifique publié en 1996 (fr) im Oktober 1996 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'ochobre de 1996 (ast) scientific article published on 01 October 1996 (en)
publication date	wds:Q71650797-65CCADA4-4E89-4FB5-9D60-5E98371D37E7
publication date	1996-10-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71650797-46E3197D-9114-4427-9984-BA609BB94013
language of work or name	English
author name string	wds:Q71650797-1B9A5CED-BA04-46D1-A0A9-4DC108610AA1 wds:Q71650797-2FF00A03-645A-4117-8BA8-2CF836EA01A8 wds:Q71650797-304E9A1E-E08E-404D-89D9-EF9AE1469504 wds:Q71650797-38E6EE1E-0587-4C7B-BA3F-EE7AA473F413 wds:Q71650797-3AC16120-75ED-4C04-9F7E-00DD6888F742 wds:Q71650797-3BE38868-CCFD-406F-9D28-05D99382D581
author name string	Zarski JP Cohard M Leroy V Opolon P Thevenot T Mathurin P
rdfs:label	Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration (en) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration (nl)
skos:prefLabel	Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration (en) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration (nl)
name	Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration (en) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration (nl)
author	wds:Q71650797-D8BD77B4-1FD9-4B29-A8CC-F4C8C390EEB8
author	Thierry Poynard
title	wds:Q71650797-28D188A1-3042-42E2-B9F4-9EF0D3E220B5
title	Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration (en)
page(s)	wds:Q71650797-108079E5-711B-4B30-9097-C1689B620F24
page(s)	778-789
instance of	wds:Q71650797-0e009f34-7a54-4730-8b6c-c15f7aff29a5 wds:Q71650797-E2784977-9A4D-42D3-8A81-268E8367A4D6
instance of	meta-analysis scholarly article
main subject	wds:Q71650797-1424411F-6973-4351-9F74-EBB8D6E16C65 wds:Q71650797-DCD4EE5C-94DB-42AD-8161-C4D2A8E86CD3 wds:Q71650797-F76D1A43-2613-4E51-998F-FC988837191D
main subject	hepatitis C meta-analysis viral hepatitis
PubMed ID	wds:Q71650797-E25F7F2B-05AA-4D61-B3A5-589333072252
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8855176
PubMed ID	8855176
published in	wds:Q71650797-3BBD14D9-C43A-4ABC-8BE5-E1AE8ECE9541
published in	Hepatology
issue	wds:Q71650797-6E41C4E6-0400-453D-B064-688DE994B207
volume	wds:Q71650797-BCDA9030-9272-4EB5-925C-7F0D74721F48
issue	4
volume	24
DOI	wds:Q71650797-5BDFF7F6-E7CD-484B-B40F-D9D100B319F5
DOI	http://dx.doi.org/10.1002/HEP.510240405
DOI	10.1002/HEP.510240405
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71650797
is cites work of	Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response Comparative Analysis of Anti-Hepatitis C Virus Activity and Gene Expression Mediated by Alpha, Beta, and Gamma Interferons Combination treatment with interferon and ribavirin for chronic hepatitis C. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice Hepatitis C Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C. Adenovirus-mediated gene transfer of interferon alpha inhibits hepatitis C virus replication in hepatocytes Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic Evolution of interferon-based therapy for chronic hepatitis C. Optimal clinical trial designs for immune-based therapies in persistent viral infections Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus Interferon for interferon naive patients with chronic hepatitis C. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Managing Occupational Risks for Hepatitis C Transmission in the Health Care Setting Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients The epidemiology of hepatitis C in a UK health regional population of 5.12 million Antiviral therapy for chronic hepatitis C: past, present, and future Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays Hepatitis C Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Interferon for acute hepatitis C. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway Pegylated interferons for the treatment of chronic hepatitis C infection Interferon alpha (IFNalpha) and psychiatric syndromes: a review Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. Modulation of interferon expression by hepatitis C virus NS5A protein and human homeodomain protein PTX1 Pathogenesis, diagnosis and management of hepatitis C. Neuropsychiatric adverse effects of interferon-alpha: recognition and management Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc) Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software